Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
TARS on Nasdaq
Shares outstanding
42,194,093
Price per share
$81.89
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
44,886,095
Total reported value
$2,667,310,850
% of total 13F portfolios
0%
Share change
-1,301,428
Value change
-$49,487,109
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
216
Price from insider filings
$82.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 8.1% $183,878,466 3,424,180 RTW Investments, LP 30 Jun 2025
BlackRock, Inc. 7.4% $143,595,686 3,092,735 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.1% +25% $178,290,000 +$38,453,587 3,000,000 +27% Deep Track Capital, LP 30 Sep 2025
TANG CAPITAL MANAGEMENT LLC 5.9% $113,976,225 2,454,797 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
MORGAN STANLEY 4.7% $90,234,523 1,943,453 Morgan Stanley 31 Mar 2025
Cowen Financial Products LLC 4.9% $88,645,456 1,909,228 Cowen Financial Products LLC 31 Dec 2024
As of 30 Sep 2025, Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) has 216 institutional shareholders filing 13F forms. They hold 44,886,095 shares .

Top 25 institutional shareholders own 85% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9% 3,779,621 -0.33% 0% $224,622,876
RTW INVESTMENTS, LP 7.5% 3,177,436 +2.1% 2.3% $188,835,021
Deep Track Capital, LP 7.1% 3,000,000 +71% 5% $178,290,000
Paradigm Biocapital Advisors LP 6.3% 2,665,698 -10% 4.7% $158,422,432
JENNISON ASSOCIATES LLC 6.2% 2,604,580 +5.5% 0.09% $154,790,191
TANG CAPITAL MANAGEMENT LLC 5.8% 2,454,797 0% 5.6% $145,888,586
VANGUARD GROUP INC 5.4% 2,272,090 -1.1% 0% $135,030,309
MORGAN STANLEY 4.5% 1,912,402 -7% 0.01% $113,654,091
JANUS HENDERSON GROUP PLC 3.4% 1,438,999 -20% 0.04% $85,554,237
Assenagon Asset Management S.A. 3% 1,247,954 +25% 0.11% $74,165,906
Frazier Life Sciences Management, L.P. 2.8% 1,167,527 -16% 2.1% $69,386,130
Driehaus Capital Management LLC 2.4% 1,031,041 +18% 0.44% $61,274,767
LORD, ABBETT & CO. LLC 2.3% 985,629 -0.98% 0.17% $58,575,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 944,496 +1.1% 0% $56,140,457
Invesco Ltd. 2.2% 937,006 +0.92% 0.01% $55,686,267
STATE STREET CORP 2.2% 936,162 -4.6% 0% $55,636,108
MACQUARIE GROUP LTD 2% 833,437 -12% 0.06% $49,531,000
TORONTO DOMINION BANK 1.5% 617,583 -38% 0.07% $36,702,958
D. E. Shaw & Co., Inc. 1.4% 598,307 -17% 0.03% $35,557,385
Clearbridge Investments, LLC 1.3% 566,978 +28% 0.03% $33,695,506
Artisan Partners Limited Partnership 1.3% 558,326 +3.5% 0.05% $33,181,314
BANK OF AMERICA CORP /DE/ 1.3% 536,023 +15% 0% $31,855,847
Qube Research & Technologies Ltd 1.2% 522,276 +14% 0.04% $31,038,863
Ensign Peak Advisors, Inc 1.1% 482,364 -1% 0.05% $28,666,893
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 452,857 +18% 0% $26,914,000

Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 1,141,712 $93,483,525 -$9,238,462 8,188.63% 6
2025 Q3 44,886,095 $2,667,310,850 -$49,487,109 5,943% 216
2025 Q2 46,131,357 $1,868,819,935 +$92,954,247 4,051% 204
2025 Q1 43,564,795 $2,238,109,529 +$155,550,094 5,137% 191
2024 Q4 40,257,261 $2,228,992,174 -$65,425,290 5,537% 192
2024 Q3 43,391,345 $1,426,965,026 +$102,449,516 3,289% 162
2024 Q2 40,069,329 $1,089,076,999 +$12,486,301 2,718% 149
2024 Q1 39,163,541 $1,423,594,819 +$241,745,001 3,635% 154
2023 Q4 11,442 $231,701 +$231,701 2,025% 1
2023 Q3 29,793,106 $529,411,034 +$139,188,117 1,777% 105
2023 Q2 21,435,682 $387,312,182 +$39,178,152 1,807% 92
2023 Q1 20,057,814 $252,130,286 -$6,024,605 1,257% 73
2022 Q4 20,519,699 $300,819,987 +$13,982,703 1,466% 65
2022 Q3 20,489,091 $350,771,070 +$9,470,918 1,712.01% 72
2022 Q2 19,921,482 $290,851,823 +$98,103,713 1,460% 66
2022 Q1 13,199,169 $222,025,113 +$2,268,000 1,682% 49
2021 Q4 13,061,832 $293,966,317 +$4,706,910 2,250% 42
2021 Q3 12,869,545 $277,366,450 -$12,956,592 2,155.01% 44
2021 Q2 13,053,454 $378,290,053 -$6,901,273 2,898.05% 43
2021 Q1 12,761,893 $410,350,129 -$213,787 3,223.08% 41
2020 Q4 12,759,585 $523,637,183 +$523,637,032 4,133% 39